Background
Aims
Materials and methods
Salivary scintigraphy
Dose–response analysis
Results
Characteristics
|
Number
|
---|---|
Age:
| |
Median | 54 years |
Range | 33-65 years |
Gender:
| |
Male | 37 (90.2%) |
Female | 04 (09.8%) |
Primary site:
| |
Oropharynx | 23 (56.1%) |
Larynx | 10 (24.4%) |
Hypopharynx | 08 (19.5%) |
Laterality (epicentre):
| |
Right | 22 (53.7%) |
Left | 18 (43.9%) |
Midline | 01 (02.4%) |
American Joint Committee on Cancer (AJCC) staging:
| |
Stage II | 09 (21.9%) |
Stage III | 17 (41.5%) |
Stage IV | 15 (36.6%) |
Radiotherapy technique:
| |
Three-Dimensional Conformal Radiotherapy (3D-CRT) | 20 (48.8%) |
Intensity-Modulated Radiation Therapy (IMRT) | 21 (51.2%) |
Median (inter-quartile range) of mean parotid dose:
| |
Ipsilateral parotid | 50.0 Gy (36.2-59.7) |
Contralateral parotid | 35.4 Gy (28.0-53.5) |
Concurrent chemotherapy:
| |
Yes | 38 (92.6%) |
No | 03 (07.4%) |
Discussion
Study (ref)
|
Number of patients (N)
|
Mean parotid dose
|
Salivary scintigraphy criteria for defining severe xerostomia
|
Tolerance Dose 50 (95% CI)
| |
---|---|---|---|---|---|
6 weeks-6 months
|
1-year
| ||||
#Roesink [21] | 96 (conv) | 33.14Gy | SEF ratio <45% | 29Gy (25-34Gy) | 43Gy (37-51Gy) |
Munter [26] | 18 (IMRT) | NR | SEF ratio <50% | 34.8Gy (27.6-42Gy) | NR |
Munter [27] | 33 (conv) | 60.6Gy | SEF ratio <50% | 36.4Gy (20.5-42.3Gy) | NR |
19 (IMRT) | 27.7Gy | SEF ratio <50% | 35Gy (28-42Gy) | ||
*Rudat [28] | 34 (conv) | 60.7Gy | SEF ratio <50% | NR | 51.1Gy (43.5-58.7Gy) |
31 (IMRT) | 30.9Gy | ||||
Tenhunen [29] | 20 (IMRT) | 27.6Gy | SEF ratio <50% | 40.3Gy (30–53.6Gy) | 39.2Gy (27.9-50.2Gy) |
Kapanen [30] | 25 (IMRT) | 23.2Gy | SEF ratio <50% | 30.4Gy (23.2-37.6Gy) | NR |
Chen [31] | 31 (IMRT) | 51.7Gy IL | SEF ratio <45% | NR | 43.6Gy (41.3-45.9Gy) |
36.7Gy CL | |||||
Present study | 41 (3D-CRT and IMRT) | 48.3Gy IL | SEF ratio <45% | 35.1Gy (23.6-42.6Gy) | 41.3Gy (34.6-48.8) |
39.7Gy CL |